The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Nanopreparations for organelle-specific delivery in cancer
Open accessAbstract
To efficiently deliver therapeutics into cancer cells, a number of strategies have been recently investigated. The toxicity associated with the administration of chemotherapeutic drugs due to their random interactions throughout the body necessitates the development of drug-encapsulating nanopreparations that significantly mask, or reduce, the toxic side effects of the drugs. In addition to reduced side effects associated with drug encapsulation, nanocarriers preferentially accumulate in tumors as a result of its abnormally leaky vasculature via the Enhanced Permeability and Retention (EPR) effect. However, simple passive nanocarrier delivery to the tumor site is unlikely to be enough to elicit a maximum therapeutic response as the drug-loaded carriers must reach the intracellular target sites. Therefore, efficient translocation of the nanocarrier through the cell membrane is necessary for cytosolic delivery of the cargo. However, Crossing the cell membrane barrier and reaching cytosol might still not be enough for achieving maximum therapeutic benefit, which necessitates the delivery of drugs directly to intracellular targets, such as bringing pro-apoptotic drugs to mitochondria, nucleic acid therapeutics to nuclei, and lysosomal enzymes to defective lysosomes. In this review, we discuss the strategies developed for tumor targeting, cytosolic delivery via cell membrane translocation, and finally organelle-specific targeting, which may be applied for developing highly efficacious, truly multifunctional, cancer-targeted nanopreparations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Human epidermal receptor-2 (HER-2) is over-expressed in a majority of patients with breast cancer [37–39].”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“Several nanopreparations have emerged as potentially useful cancer therapeutics [15].”
BackgroundFang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Cellular uptake of the tat protein from human immunodeficiency virus
Frankel, A. D., & Pabo, C. O. (1988) · Cell · doi:10.1016/0092-8674(88)90263-2 · Cited by 2,783
Cited by
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Nanocarriers for cancer-targeted drug delivery
Kumari, P., Ghosh, B., & Biswas, S. (2016) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1051049 · Cited by 607
Self-citationA holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Xie, J., Bi, Y., Zhang, H., Dong, S., Teng, L., Lee, R. J., & Yang, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00697 · Cited by 466
Silk fibroin nanoparticle as a novel drug delivery system
Mottaghitalab, F., Farokhi, M., Shokrgozar, M. A., Atyabi, F., & Hosseinkhani, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.03.020 · Cited by 444
Yang, G., Xu, L., Xu, J., Zhang, R., Song, G., Chao, Y., Feng, L., Han, F., Dong, Z., Li, B., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00040 · Cited by 397
Ramasamy, T., Ruttala, H. B., Gupta, B., Poudel, B. K., Choi, H.-G., Yong, C. S., & Kim, J. O. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.043 · Cited by 373
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
Borrelli, A., Tornesello, A., Tornesello, M., & Buonaguro, F. (2018) · Molecules · doi:10.3390/molecules23020295 · Cited by 295
Supramolecular “Trojan Horse” for Nuclear Delivery of Dual Anticancer Drugs
Cai, Y., Shen, H., Zhan, J., Lin, M., Dai, L., Ren, C., Shi, Y., Liu, J., Gao, J., & Yang, Z. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12322 · Cited by 293
Magnetic Nanoparticles in Targeted Drug Delivery: a Review
kianfar, E. (2021) · Journal of Superconductivity and Novel Magnetism · doi:10.1007/s10948-021-05932-9 · Cited by 280
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Kumari, P., Muddineti, O. S., Rompicharla, S. V. K., Ghanta, P., B B N, A. K., Ghosh, B., & Biswas, S. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1245365 · Cited by 79
Self-citationJoy, R., George, J., & John, F. (2022) · ChemistrySelect · doi:10.1002/slct.202104045 · Cited by 50
Maity, A. R., & Stepensky, D. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b10295 · Cited by 44
Chen, Q., Long, M., Qiu, L., Zhu, M., Li, Z., Qiao, M., Hu, H., Zhao, X., & Chen, D. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s111950 · Cited by 16
Metadata
- Authors
- Biswas, S., & Torchilin, V. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 66
- Pages
- 26-41
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2094439964
- Cited by
- 292
- References
- 213
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.